ORR increases to 82% with additional Partial Response in azer-cel CAR T Relapsed Ph 1b trial December 2, 2025
Ph 3 Trial of Sac-TMT in Combination with KEYTRUDA as 1L Treatment for PD-L1-Positive NSCLC Met Primary Endpoint December 2, 2025
Clinical results of glecirasib in combination with JAB-3312 (sitneprotafib) in KRAS G12C–mutated NSCLC published in The Lancet Respiratory Medicine December 2, 2025
The Annals of Oncology Publishes Results of Ph 2 Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma December 2, 2025
Data from Acclaim-1 Ph 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer December 2, 2025
Update from ongoing TEM-GBM study in newly diagnosed GBM patients with an unmethylated gene promoter announced December 2, 2025
Positive HERIZON-GEA-01 Ph 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted New SOC in 1L HER2+ve LA/M Gastroesophageal Adenocarcinoma November 24, 2025
Statistical analysis of primary efficacy endpoints in Ph 2 trial conducted of MCS-8 (PCP) in prostate cancer completed November 24, 2025
Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML published in the Journal of Hematology & Oncology November 24, 2025
Ph 3 STELLAR clinical study results showing clinically meaningful benefits with eflornithine + lomustine in patients with grade 3 astrocytoma November 24, 2025
Positive Results Reported from Bezuclastinib PEAK Ph 3 Trial in Gastrointestinal Stromal Tumors (GIST) November 18, 2025
77.8% Three-Month Complete Response Rate Reported from Ph 3 UTOPIA Trial of UGN-103; FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Received November 10, 2025
FAILED TRIAL: Ph 3 ASCENT-07 study of Trodelvy® (sacituzumab govitecan-hziy) vs chemo in 1L HR+/HER2-neg metastatic breast cancer patients did not meet the primary endpoint of PFS November 10, 2025
Positive Data from ANTLER Ph 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010) Announced November 10, 2025
Positive Findings from Longer-Term Analysis of Ph 3 INDIGO Trial Showing Continued Durable Benefit of VORANIGO® (vorasidenib) Published in The Lancet Oncology November 10, 2025
Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers published in eBioMedicine November 4, 2025
KEYTRUDA + WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell RCC Following Nephrectomy November 4, 2025
FAILED TRIAL: Ph 3 LEAP-012 trial of KEYTRUDA + LENVIMA + TACE combo in HCC patients did not achieve statistical significance for OS vs TACE alone November 4, 2025
SIOP 2025: Latest data of zurletrectinib (ICP-723) for the treatment of pediatric and adolescent patients with advanced solid tumors announced November 4, 2025
